Living donor liver transplantation to a survivor of liver resection for hepatocellular carcinoma with major portal vein invasion.
Hiroshi Sadamori(Okayama University), Toshiyoshi Fujiwara(Okayama University), Masashi Utsumi(Okayama University), Daisuke Sato(Okayama University), Yuzo Umeda(Okayama University), Susumu Shinoura(Okayama University), Takahito Yagi(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Ryuichi Yoshida(Okayama University)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer
|JCI Insight|2018|148
The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer
|Journal of Experimental & Clinical Cancer Research|2018|111